Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic paces ahead

This article was originally published in The Gray Sheet

Executive Summary

Firm's Adapta, Versa and Sensia pacemakers offer "managed ventricular pacing" and "atrial capture management" to provide stimulation only as needed, the company said upon announcing the launch of the products. The technology has been shown to eliminate 99% of unnecessary pacing, reducing the risk of developing co-morbidities such as heart failure and atrial fibrillation, Medtronic says. The firm has been looking forward to this launch as a means of reasserting its hold on a vulnerable cardiac rhythm management market (1"The Gray Sheet" Feb. 27, 2006, p. 14)...

You may also be interested in...



Medtronic Readies New CRM Products To Protect Share Taken From Guidant

Medtronic is prepping three pacemakers for launch by May to compete against new products from competitor St. Jude and buttress against Guidant's potential comeback

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

UsernamePublicRestriction

Register

MT023900

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel